Loading cancer entity…
Loading cancer entity…
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06613841 | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma(GBM) | recruiting | Early Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | active not recruiting | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 9, 2026 |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial | terminated | Early Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04869449 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | terminated | Early Phase 1 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials